Brief: Jw (Cayman) Therapeutics Receives Investigational New Drug Clearance From NMPA Of China
10/04/2023 13:48
April 10 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* RECEIVED INVESTIGATIONAL NEW DRUG CLEARANCE FROM NMPA OF
CHINA
* CLEARANCE FOR A CLINICAL TRIAL OF RELMACABTAGENE
AUTOLEUCEL
INJECTION
Source text for Eikon: ID:nHKS7hlVDs
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License